Search Within

Melanoma Disease Management Team

Formats
  1. Journal Article (1604)
  2. Meeting Abstract (791)
  3. Book Section (104)
  4. Review (72)
  5. Editorial (58)
  6. Research Letter (45)
  7. Guidelines (26)
  8. Conference Paper (22)
  9. Correspondence (21)
  10. Miscellaneous (16)
  11. Book Whole (11)
Groups
  1. Department of Medicine (1690)
  2. Survivorship Research (1193)
  3. Solid Tumor Oncology Division (1052)
  4. Department of Pathology and Laboratory Medicine (957)
  5. Surgery (947)
  6. Melanoma and Immunotherapeutics Service (793)

More Groups

People
  1. Klaus Busam (698)
  2. Daniel Coit (543)
  3. Allan Halpern (401)
  4. Michael Postow (369)
  5. Alexander Shoushtari (247)
  6. Jedd Wolchok (222)

More People

Years
  1. 2025 (89)
  2. 2024 (138)
  3. 2023 (160)
  4. 2022 (167)
  5. 2021 (149)
  6. 2020 (142)

More Years

Publications
  1. Journal of Clinical Oncology (269)
  2. Annals of Surgical Oncology (221)
  3. Journal of the American Academy of Dermatology (123)
  4. Journal of Investigative Dermatology (84)
  5. Modern Pathology (67)
  6. American Journal of Surgical Pathology (64)

More Publications

Publishers
  1. Springer (341)
  2. American Society of Clinical Oncology (284)
  3. Elsevier Inc. (231)
  4. Lippincott Williams & Wilkins (229)
  5. Wiley Blackwell (162)
  6. Elsevier Science, Inc. (160)

More Publishers

Results (2770)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Repeat dosing of oncolytic adenovirus ONCOS-102 is associated with enhanced and persistent immune responses and improved systemic activity in anti-PD-1 resistant/refractory (R/R) melanoma
    Meeting Abstract

    Shoushtari, A.; Ottesen, L.; Levitsky, V.; Hansen, T. B.; Hornyak, T.; Olszanski, A.; Nyakas, M.; Wolchok, J.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Immunogenic landscape and therapeutic targeting of mutant NRAS "public" neoantigens
    Meeting Abstract

    Etxeberria, I.; Banks, L.; Chandran, S.; Correa, A.; Novak, B.; Fleischman, J.; Drilon, A.; Wolchok, J.; Merghoub, T.; Klebanoff, C.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Examining the impact of chromosomal instability on mucosal melanoma tumor infiltrate and responses to PD-1 based therapy
    Meeting Abstract

    Armstrong, E.; Gottesdiener, L.; Schultz, N.; Bakhoum, S. F.; Hollmann, T. J.; Shoushtari, A.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Modulation of immune gene expression by intra-tumoral oncolytic adenovirus ONCOS-102 is associated with clinical response in anti-PD-1 refractory/resistant melanoma
    Meeting Abstract

    Wiklund, E. D.; Kuryk, L.; Kumar, S.; Jaderberg, M.; Levitsky, V.; Hansen, T. B.; Moller, A. S.; Shoushtari, A.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Oral beta-glucan enhanced anti-ganglioside antibody titer after vaccination against high- risk neuroblastoma: Results of a randomized trial
    Meeting Abstract

    Cheung, I. Y.; Mauguen, A.; Feng, Y.; Ragupathi, G.; Basu, E.; Roberts, S. S.; Modak, S.; Kushner, B. H.; Cheung, N. K. V.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • PIK3CA hotspot mutation generates a shared neoantigen targetable by TCR gene therapy
    Editorial

    Klebanoff, C. A.; Chandran, S. S.
    Nature Medicine (2022)

    Fulltext@MSK | Save
  • The potential for technology to aid quantitative assessment in cutaneous T cell lymphoma
    Correspondence

    Gu, L.; Oh, Y.; Smith, M. P.; Kurtansky, N. R.; Horwitz, S.; Kahn, N.; Moskowitz, A.; Noor, S. J.; Myskowski, P.; Rotemberg, V.
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable/metastatic, BRAF V600-or NRAS-mutant melanoma
    Meeting Abstract

    Lebbe, C.; Long, G. V.; Robert, C.; Hamid, O.; Atkinson, V. G.; Shoushtari, A. N.; Daud, A.; Bechter, O. E.; Schadendorf, D.; Sullivan, R. J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Long-term survivors on tebentafusp in phase II trial of previously treated patients with metastatic uveal melanoma
    Meeting Abstract

    Sato, T.; Ikeguchi, A. P.; Nathan, P.; Carvajal, R. D.; Shoushtari, A. N.; Gajewski, T. F.; Hassel, J. C.; Rioth, M.; Leyvraz, S.; Daniels, G. A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma
    Meeting Abstract

    Schlaak, M.; Dummer, R.; Kirkwood, J. M.; Joshua, A.; Milhem, M.; Gastaud, L.; Mauch, C.; Yushak, M. L.; Lockwood, S.; Hayes, C.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save